MoneyWorks4Me

Natco Pharma informs about press release

26 Apr 2021 Evaluate

Natco Pharma has informed that it has enclosed a press Release on 26th April 2021, titled ‘NATCO seeks Emergency approval of Molnupiravir capsules for Covid-19 treatment’.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

874.15 -9.30 (-1.05%)
25-Aug-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1902.20
Dr. Reddys Labs. 1187.30
Cipla 1420.20
Lupin 2179.50
Zydus Lifesciences 1101.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: